Drug Type miRNA, AAV based gene therapy |
Synonyms |
Target |
Mechanism Ube3a-ATS modulators(small nucleolar RNA host gene 14 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Encoded Therapeutics, Inc.Startup |
Active Organization Encoded Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Angelman Syndrome | Preclinical | US | Encoded Therapeutics, Inc.Startup | 07 May 2024 |